Literature DB >> 20601459

Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease.

Damir Hamamdzic1, Robert S Fenning, Dhavalkumar Patel, Emile R Mohler, Ksenia A Orlova, Alexander C Wright, Raul Llano, Martin G Keane, Richard P Shannon, Morris J Birnbaum, Robert L Wilensky.   

Abstract

Atherosclerosis is an inflammatory process leading to enhanced cellular proliferation, apoptosis, and vasa vasorum (VV) neovascularization. While both diabetes mellitus (DM) and hypercholesterolemia (HC) predispose to atherosclerosis, the precise interaction of these risk factors is unclear. Akt is a central node in signaling pathways important for inflammation, and we hypothesized that DM/HC would lead to aberrant Akt signaling and advanced, complex atherosclerosis. DM was induced in pigs by streptozotocin and HC by a high-fat diet. Animals were randomized to control (non-DM, non-HC), DM only, HC only, and DM/HC groups. Coronary artery homogenates were analyzed by immunoblotting for proteins involved in the Akt pathway, including phosphorylated (p)-Akt (Ser473), p-GSK-3beta (Ser9), activated NF-kappaB p65, and VEGF. Immunohistochemical staining for Ki67 (cell proliferation), terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) (apoptosis), and von Willebrand factor (vWF) (neovascularization) was performed. Neovascularization was visualized with micro-computerized tomography (CT). Only DM/HC animals developed advanced atherosclerosis and showed decreased p-Akt (Ser473) and p-GSK-3beta (Ser9) levels (P < 0.01 and P < 0.05, respectively). DM/HC arteries demonstrated increased cellular proliferation (P < 0.001), apoptosis (P < 0.01), and activation of NF-kappaB p65 (P < 0.05). Induction of DM/HC also resulted in significant VV neovascularization by enhanced VEGF expression (P < 0.05), increased vWF staining (P < 0.01), and increased density by micro-CT. In conclusion, DM and HC synergistically resulted in complex atherosclerosis associated with attenuated p-Akt (Ser473) levels. Aberrant Akt signaling correlated with increased inflammation, cellular proliferation, apoptosis, and VV neovascularization. Our results revealed a synergistic effect of DM and HC in triggering abnormal Akt signaling, resulting in advanced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601459      PMCID: PMC2944488          DOI: 10.1152/ajpheart.00071.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  62 in total

1.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element.

Authors:  N M Mazure; E Y Chen; K R Laderoute; A J Giaccia
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

Review 2.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

Review 3.  Membrane translocation and activation of the Akt kinase in growth factor-stimulated hematopoietic cells.

Authors:  J R Testa; A Bellacosa
Journal:  Leuk Res       Date:  1997 Nov-Dec       Impact factor: 3.156

4.  Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia.

Authors:  H M Kwon; G Sangiorgi; E L Ritman; C McKenna; D R Holmes; R S Schwartz; A Lerman
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

5.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

6.  Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling.

Authors:  Heath D Skinner; Jenny Z Zheng; Jing Fang; Faton Agani; Bing-Hua Jiang
Journal:  J Biol Chem       Date:  2004-08-26       Impact factor: 5.157

7.  Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability.

Authors:  Pedro R Moreno; K Raman Purushothaman; Valentin Fuster; Dario Echeverri; Helena Truszczynska; Samin K Sharma; Juan J Badimon; William N O'Connor
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

8.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries.

Authors:  E R Edelman; M A Nugent; L T Smith; M J Karnovsky
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

9.  Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions.

Authors:  M A Ramos; M Kuzuya; T Esaki; S Miura; S Satake; T Asai; S Kanda; T Hayashi; A Iguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

10.  Angiogenesis in human coronary atherosclerotic plaques.

Authors:  E R O'Brien; M R Garvin; R Dev; D K Stewart; T Hinohara; J B Simpson; S M Schwartz
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

View more
  16 in total

1.  Rutin inhibits coronary heart disease through ERK1/2 and Akt signaling in a porcine model.

Authors:  Lin Lv; Yucai Yao; Gang Zhao; Guiyue Zhu
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

2.  Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis.

Authors:  Noemi Rotllan; Amarylis C Wanschel; Ana Fernández-Hernando; Alessandro G Salerno; Stefan Offermanns; William C Sessa; Carlos Fernández-Hernando
Journal:  Circ Res       Date:  2015-04-13       Impact factor: 17.367

3.  Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs.

Authors:  Rozh H Al-Mashhadi; Martin M Bjørklund; Martin B Mortensen; Christina Christoffersen; Torben Larsen; Erling Falk; Jacob F Bentzon
Journal:  Diabetologia       Date:  2015-05-31       Impact factor: 10.122

4.  Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes.

Authors:  C H Leo; J L Hart; O L Woodman
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  ER stress, p66shc, and p-Akt/Akt mediate adjuvant-induced inflammation, which is blunted by argirein, a supermolecule and rhein in rats.

Authors:  Xiao-Dong Cong; Ming-Jian Ding; De-Zai Dai; You Wu; Yun Zhang; Yin Dai
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

6.  Prevention of hyperglycemic signal pathways in metabolic syndrome carotid artery of rats.

Authors:  Hiromi Kawai; Fengfeng Tian; Tomoko Kurata; Kentaro Deguchi; Toru Yamashita; Yoshio Omote; Syoichiro Kono; Koji Abe
Journal:  Transl Stroke Res       Date:  2012-08-14       Impact factor: 6.829

7.  Everolimus-eluting stents improve vascular response in a diabetic animal model.

Authors:  Anwer Habib; Vinit Karmali; Michael C John; Rohini Polavarapu; Gaku Nakazawa; Kim Pachura; Talina Davis; Frank D Kolodgie; Renu Virmani; Aloke V Finn
Journal:  Circ Cardiovasc Interv       Date:  2014-06-10       Impact factor: 6.546

Review 8.  [Update on diabetic macroangiopathy].

Authors:  J Kunz
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

9.  TMEM16A channel upregulation in arterial smooth muscle cells produces vasoconstriction during diabetes.

Authors:  M Dennis Leo; Dieniffer Peixoto-Nieves; Wen Yin; Somasundaram Raghavan; Padmapriya Muralidharan; Alejandro Mata-Daboin; Jonathan H Jaggar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-15       Impact factor: 4.733

Review 10.  Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia.

Authors:  Damir Hamamdzic; Robert L Wilensky
Journal:  J Diabetes Res       Date:  2013-06-13       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.